Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Mind Medicine Inc (MMED.NE)
Mind Medicine Inc (MMED.NE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 194,459
  • Shares Outstanding, K 40,095
  • Annual Sales, $ 0 K
  • Annual Income, $ -56,796 K
  • 60-Month Beta 3.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.50
Trade MMED.NE with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -1.87
  • Most Recent Earnings -0.45 on 11/02/23
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.3000 +44.55%
on 11/20/23
5.1850 -8.00%
on 12/04/23
+0.5100 (+11.97%)
since 11/03/23
3-Month
3.3000 +44.55%
on 11/20/23
6.1100 -21.93%
on 09/12/23
-0.6200 (-11.50%)
since 09/05/23
52-Week
2.8800 +65.62%
on 12/29/22
6.8000 -29.85%
on 08/01/23
+0.9300 (+24.22%)
since 12/05/22

Most Recent Stories

More News
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031

EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END

CYBN.NE : 0.5900 (-1.67%)
MMED.NE : 4.7700 (-1.65%)
CYBN : 0.4345 (-2.86%)
CMPS : 5.65 (-7.38%)
SEEL : 1.4400 (-26.53%)
MNMD : 3.49 (-3.32%)
NUMIF : 0.0835 (-7.43%)
NUMI.TO : 0.1150 (-11.54%)
MindMed Reports First Quarter 2023 Financial Results and Business Highlights

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 4.7700 (-1.65%)
MNMD : 3.49 (-3.32%)
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy

The Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product...

MMED.NE : 4.7700 (-1.65%)
MNMD : 3.49 (-3.32%)
INCY : 54.82 (-0.25%)
SGEN : 215.83 (+1.27%)
PFE : 29.09 (-0.65%)
FBRX : 0.4950 (-1.00%)
JAZZ : 121.49 (+0.03%)
ALC : 72.08 (-1.57%)
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 4.7700 (-1.65%)
MNMD : 3.49 (-3.32%)
MindMed to Participate in May Investor Conferences

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 4.7700 (-1.65%)
MNMD : 3.49 (-3.32%)
MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 4.7700 (-1.65%)
MNMD : 3.49 (-3.32%)
INCY : 54.82 (-0.25%)
BMY : 50.23 (+0.50%)
SGEN : 215.83 (+1.27%)
FBRX : 0.4950 (-1.00%)
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced...

MMED.NE : 4.7700 (-1.65%)
MNMD : 3.49 (-3.32%)
MindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate Secretary

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 4.7700 (-1.65%)
MNMD : 3.49 (-3.32%)
CARM : 2.49 (-5.32%)
MODL : 31.37 (+0.03%)
MindMed Reports Full Year 2022 Financial Results and Business Highlights

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 4.7700 (-1.65%)
MNMD : 3.49 (-3.32%)
MindMed to Participate in March Investor Conferences

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MMED.NE : 4.7700 (-1.65%)
MNMD : 3.49 (-3.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 5.0500
2nd Resistance Point 4.9900
1st Resistance Point 4.8800
Last Price 4.7700
1st Support Level 4.7100
2nd Support Level 4.6500
3rd Support Level 4.5400

See More

52-Week High 6.8000
Fibonacci 61.8% 5.3026
Fibonacci 50% 4.8400
Last Price 4.7700
Fibonacci 38.2% 4.3774
52-Week Low 2.8800

See More

Business Summary

Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar